Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 223

Sort by

Sort Order Select

Journal Articles

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Dan T Vogl, Shebli Atrash, Sarah A Holstein, Omar Nadeem, Don M Benson, Jr, Maria Chaudhry, Noa Biran, Kaveri Suryanarayan, Cheryl Li, Yuyin Liu, Sabrina Christine Collins, Xavier Parot, Jonathan L Kaufman

Blood blood.2024026124.

https://doi.org/10.1182/blood.2024026124

Published: 2024

Includes: Supplemental data

Journal Articles

Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM)

Nisha S. Joseph, Jonathan L. Kaufman, Craig C. Hofmeister, Vikas A. Gupta, Bryan J Burton, Roseann M Pruitt, Ajay K. Nooka, Madhav V. Dhodapkar, Sagar Lonial

Blood (2024) 144 (Supplement 1): 1983.

https://doi.org/10.1182/blood-2024-210335

Published: 2024

Journal Articles

Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma

Blood (2024) 144 (Supplement 1): 1993.

https://doi.org/10.1182/blood-2024-205614

Published: 2024

Journal Articles

Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting

Craig C. Hofmeister, Mingyuan Zhang, Vikas A. Gupta, Nisha S. Joseph, Jonathan L. Kaufman, Ajay K. Nooka, Madhav V. Dhodapkar, Sagar Lonial, Douglas W. Sborov

Blood (2024) 144 (Supplement 1): 5152.

https://doi.org/10.1182/blood-2024-202100

Published: 2024

Journal Articles

The Anti-BCMA Antibody-Drug Conjugate Hdp-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma

Robert Z. Orlowski, Shambavi Richard, Jonathan L. Kaufman, Sebastian Grosicki, Istvan Takacs, Andras Strassz, Andreas Martin Pahl, Michael Kulke, Thorsten Michael, Anette Last, Hajnalka Szaboki, Frank Richard, Oliver Schönborn-Kellenberger, Marc S. Raab

Blood (2024) 144 (Supplement 1): 3381.

https://doi.org/10.1182/blood-2024-210088

Published: 2024

Journal Articles

Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)

Lilly Gu, Nisha S. Joseph, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Jonathan L. Kaufman

Blood (2024) 144 (Supplement 1): 3780.

https://doi.org/10.1182/blood-2024-211474

Published: 2024

Journal Articles

Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies

Lorenzo Cani, Sara A. Scott, Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Jonathan L. Kaufman

Blood (2024) 144 (Supplement 1): 3311.

https://doi.org/10.1182/blood-2024-206155

Published: 2024

Journal Articles

A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma

Craig C. Hofmeister, Vikas A. Gupta, Jonathan L. Kaufman, Ajay K. Nooka, Nisha S. Joseph, Sagar Lonial, Madhav V. Dhodapkar

Blood (2024) 144 (Supplement 1): 255.

https://doi.org/10.1182/blood-2024-202102

Published: 2024

Journal Articles

Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers

Shree Allada, Vikas A. Gupta, Craig C. Hofmeister, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Nisha S. Joseph

Blood (2024) 144 (Supplement 1): 7861.

https://doi.org/10.1182/blood-2024-210996

Published: 2024

Journal Articles

Impact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)

Nisha S. Joseph, Shruti Gupta, Jonathan L. Kaufman, Sara Dicamillo, Danielle Roberts, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka

Blood (2024) 144 (Supplement 1): 7870.

https://doi.org/10.1182/blood-2024-211988

Published: 2024

Journal Articles

Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes

Cindy Varga, Myra Robinson, Vikas Gupta, Craig C. Hofmeister, Ajay K. Nooka, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Shanice Borden, Christopher Ferreri, Barry Paul, Shebli Atrash, Manisha Bhutani, Peter M. Voorhees, Nisha S. Joseph

Blood (2024) 144 (Supplement 1): 4702.

https://doi.org/10.1182/blood-2024-204388

Published: 2024

Journal Articles

Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade

Gabriel Najarro, Vikas A. Gupta, Nisha S. Joseph, Jonathan L. Kaufman, Ajay K. Nooka, Madhav V. Dhodapkar, Sagar Lonial, Craig C. Hofmeister

Blood (2024) 144 (Supplement 1): 5142.

https://doi.org/10.1182/blood-2024-202078

Published: 2024

Journal Articles

A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy

Craig C. Hofmeister, Vikas A. Gupta, Nisha S. Joseph, Sagar Lonial, Madhav V. Dhodapkar, Ajay K. Nooka, Jonathan L. Kaufman

Blood (2024) 144 (Supplement 1): 4672.

https://doi.org/10.1182/blood-2024-203485

Published: 2024

Journal Articles

Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2

Shannon M Matulis, Robert M Chavez, Rebecca Owens, Arun P Wiita, Mala Shanmugam, Ricardo De Matos Simoes, Constantine S Mitsiades, Nisha S. Joseph, Craig C. Hofmeister, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Vikas A. Gupta, Jonathan D. Licht, Benjamin G. Barwick, Lawrence H. Boise

Blood (2024) 144 (Supplement 1): 4663.

https://doi.org/10.1182/blood-2024-210441

Published: 2024

Journal Articles

Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma

Jonathan L. Kaufman, Nisha S. Joseph, Vikas A. Gupta, Sara Dicamillo, Danielle Roberts, Craig C. Hofmeister, Madhav V. Dhodapkar, Ajay K. Nooka, Sagar Lonial, Lawrence H. Boise

Blood (2023) 142 (Supplement 1): 4699.

https://doi.org/10.1182/blood-2023-181783

Published: 2023

Journal Articles

Initial Results from a Phase 1 Dose-Escalation Study of WVT078, a BCMA×CD3 Bispecific Antibody, in Combination with WHG626, a Gamma-Secretase (GS) Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma

Fredrik Schjesvold, Andrew Spencer, Yael C. Cohen, Enrique M Ocio, Jordi López-Pardo, Anna Maria Cafro, Natalie S. Callander, Jonathan L. Kaufman, Meera Mohan, Martin Wermke, Noriko Doki, Rebecca Kan, Karolina Kulec, Gina Trabucco, Stan Ye, Romain Sechaud, Cornelia Quadt, Raghav Chawla, Marc S. Raab

Blood (2023) 142 (Supplement 1): 4752.

https://doi.org/10.1182/blood-2023-177908

Published: 2023

Journal Articles

A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study

Ajay K. Nooka, Nisha S. Joseph, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Bryan J Burton, Hafsa M Ahmed, Darrian Linton, Annelore Cortoos, Thomas S. Lin, Richard Labotka, Stephen J. Noga, Jonathan L. Kaufman, Sagar Lonial

Blood (2023) 142 (Supplement 1): 4764.

https://doi.org/10.1182/blood-2023-190871

Published: 2023

Journal Articles

Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration

Ellen Marin, Sara Scott, Kathryn Maples, Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Jonathan L. Kaufman, Sagar Lonial, Ajay K. Nooka

Blood (2023) 142 (Supplement 1): 2008.

https://doi.org/10.1182/blood-2023-189878

Published: 2023

Journal Articles

Modakafusp Alfa Demonstrates Type I Interferon-Mediated Innate and Adaptive Immune Enhancement in a Phase 1/2 Study in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Gurpanna Saggu, Min Young Lee, Faith Dunbar, Reshma Singh, Kris Sachsenmeier, Dan T. Vogl, Shebli Atrash, Sarah A. Holstein, Omar Nadeem, Jonathan L. Kaufman, Adarsh Joshi, Kaveri Suryanarayan, Sabrina Collins

Blood (2023) 142 (Supplement 1): 3316.

https://doi.org/10.1182/blood-2023-177909

Published: 2023

Journal Articles

Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study

Marc S. Raab, Jonathan L. Kaufman, Shambavi Richard, Sebastian Grosicki, Istvan Takacs, Andras Strassz, Andreas Martin Pahl, Thorsten Michael, Anette Last, Hajnalka Szaboki, Garrit Jentsch, Oliver Schönborn-Kellenberger, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 3334.

https://doi.org/10.1182/blood-2023-182480

Published: 2023

NARROW

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM)

Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma

Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting

The Anti-BCMA Antibody-Drug Conjugate Hdp-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma

Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)

Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies

A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma

Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers

Impact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)

Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes

Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade

A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy

Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2

Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma

Initial Results from a Phase 1 Dose-Escalation Study of WVT078, a BCMA×CD3 Bispecific Antibody, in Combination with WHG626, a Gamma-Secretase (GS) Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma

A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study

Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration

Modakafusp Alfa Demonstrates Type I Interferon-Mediated Innate and Adaptive Immune Enhancement in a Phase 1/2 Study in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only